Laura B. Goddard

Array ( [id] => 16204920 [patent_doc_number] => 20200237910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => TREATMENT OF ADVANCED HER2 EXPRESSING CANCER [patent_app_type] => utility [patent_app_number] => 16/828045 [patent_app_country] => US [patent_app_date] => 2020-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23370 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828045 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16420657 [patent_doc_number] => 20200345855 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/821535 [patent_app_country] => US [patent_app_date] => 2020-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11180 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16821535 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090503 [patent_doc_number] => 20200199238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => WNT SIGNALING AGONIST MOLECULES [patent_app_type] => utility [patent_app_number] => 16/810744 [patent_app_country] => US [patent_app_date] => 2020-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090501 [patent_doc_number] => 20200199237 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => WNT SIGNALING AGONIST MOLECULES [patent_app_type] => utility [patent_app_number] => 16/810686 [patent_app_country] => US [patent_app_date] => 2020-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283777 [patent_doc_number] => 20200277379 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => PHARMACEUTICAL COMPOSITION COMBINING IMMUNOLOGIC AND CHEMOTHERAPEUTIC METHOD FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/804733 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16072 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16804733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343625 [patent_doc_number] => 20200308275 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => HER3 ANTIGEN-BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 16/805620 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16805620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19325990 [patent_doc_number] => 12043655 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-23 [patent_title] => Constitutively active chimeric cytokine receptors [patent_app_type] => utility [patent_app_number] => 16/804917 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 46 [patent_no_of_words] => 22474 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16804917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18545335 [patent_doc_number] => 11718675 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy [patent_app_type] => utility [patent_app_number] => 16/803751 [patent_app_country] => US [patent_app_date] => 2020-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 5 [patent_no_of_words] => 18360 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16803751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18315119 [patent_doc_number] => 11629188 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-18 [patent_title] => Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/803972 [patent_app_country] => US [patent_app_date] => 2020-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 79 [patent_figures_cnt] => 118 [patent_no_of_words] => 26270 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16803972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16012859 [patent_doc_number] => 20200181272 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => ANTITUMOR IMMUNE CHECKPOINT REGULATOR ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/795804 [patent_app_country] => US [patent_app_date] => 2020-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33211 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16795804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18748395 [patent_doc_number] => 11807691 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-07 [patent_title] => Compositions and methods for treatment of cancer [patent_app_type] => utility [patent_app_number] => 16/792118 [patent_app_country] => US [patent_app_date] => 2020-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 95 [patent_figures_cnt] => 139 [patent_no_of_words] => 48185 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16792118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16008879 [patent_doc_number] => 20200179282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/789401 [patent_app_country] => US [patent_app_date] => 2020-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16789401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15990533 [patent_doc_number] => 20200171137 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => NANT CANCER VACCINE [patent_app_type] => utility [patent_app_number] => 16/783734 [patent_app_country] => US [patent_app_date] => 2020-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25998 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16783734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17126239 [patent_doc_number] => 20210301007 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES INVOLVING CXCL1 FUNCTION [patent_app_type] => utility [patent_app_number] => 16/982456 [patent_app_country] => US [patent_app_date] => 2020-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18480 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16982456 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19676230 [patent_doc_number] => 12188081 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-07 [patent_title] => Bioinformatics methods of in silico validation and selection of circRNAs [patent_app_type] => utility [patent_app_number] => 16/752115 [patent_app_country] => US [patent_app_date] => 2020-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 16152 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 211 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16752115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16206571 [patent_doc_number] => 20200239561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => NODAL REGULATION OF CANCER DRUG RESISTANCE GENE [patent_app_type] => utility [patent_app_number] => 16/747419 [patent_app_country] => US [patent_app_date] => 2020-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4821 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16747419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18368159 [patent_doc_number] => 11648307 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-16 [patent_title] => Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy [patent_app_type] => utility [patent_app_number] => 16/731285 [patent_app_country] => US [patent_app_date] => 2019-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 45 [patent_no_of_words] => 25822 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16731285 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15831981 [patent_doc_number] => 20200131272 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => ANTI-CD27 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/724984 [patent_app_country] => US [patent_app_date] => 2019-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 102108 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16724984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19181060 [patent_doc_number] => 11987642 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-21 [patent_title] => Bispecific HER2 and CD3 binding molecules [patent_app_type] => utility [patent_app_number] => 16/714636 [patent_app_country] => US [patent_app_date] => 2019-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 62 [patent_no_of_words] => 38522 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 210 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16714636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18922959 [patent_doc_number] => 20240025963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES [patent_app_type] => utility [patent_app_number] => 17/311776 [patent_app_country] => US [patent_app_date] => 2019-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38825 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17311776 [rel_patent_id] =>[rel_patent_doc_number] =>)